右雷佐生

用途

• Treatment of anthracycline (doxorubicin, epirubicin, etc.) extravasation
• Treatment of anthracycline extravasation
• Prevention of doxorubicin-induced cardiomyopathy
• Prevention of doxorubicin-induced cardiomyopathy

給藥方式

可能的副作用

• Additive myelosuppression
• Potential reduction in efficacy of anthracycline antitumor agents
• Testicular atrophy (observed in dogs)
• Myelosuppression (documented in humans)
• Decreased clinical efficacy of anthracycline antineoplastic agents

注意事項與禁忌

• Should not be used unless an anthracycline antineoplastic agent is being used
• Unknown based on monograph, but generally avoid in patients not receiving anthracyclines
• > **Important**: Dexrazoxane should not be used unless an anthracycline antineoplastic agent is being administered. * **Species Limitations**: Efficacy and safety for use in cats is not known. * **Reproductive Safety**: Causes testicular atrophy in dogs when administered at usual doses for 13 weeks. Teratogenic in rats and rabbits at doses lower than human doses (FDA Category C). Nursing mothers should discontinue nursing. * **Handling Warnings**: Wear gloves when handling. Use normal procedures for handling and disposal of anti-cancer medications. If unreconstituted powder contacts skin or mucous membranes, wash off thoroughly with soap and water.

藥物相互作用

• Myelosuppressive agents: Additive myelosuppression may occur when used concurrently.
• Anthracycline antineoplastic agents: May decrease the clinical efficacy of the chemotherapy

常見問題